Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Breast cancer trial of axillary dissection versus no axillary dissection with tamoxifen in women aged 60 years or older
ACTRN12607000024448Phase 3Completed
- Sponsor
- International Breast Cancer Study Group
- Start
- Nov 1993
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tamoxifen in breast cancer (2 arms), sponsored by International Breast Cancer Study Group. Primary endpoints: Risk of recurrence in the axilla and Disease-free survival. Started Nov 1993; status: completed.
02
Drugs
tamoxifen
03
Conditions
breast cancer
Beyond the preview
Go deeper on ACTRN12607000024448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000024448.